The Addage That Prevention Is Better Than Cure In Alzheimer's and Dementia The searche for the "cure" has been disapointing. The protocols for recruitment in clinical tests for most of the players in the game have gone from including Moderate Dementia patients to only going after those having scores on above 20 MMSE or Mild … Continue reading The Real McCoy In Pursuit of Alzheimer’s Cure Is Prevention Of Deterioration, Not A “Cure”. Anavex Sciences Narrative Goes This Way. Blarcamesine $AVXL
Going Back To The Baseline These are my first impressions from looking into the simufilam data released few days ago from the 12 months open label trial. The initial data for the 6 and 9 months included only 50 subjects. The current data includes 100 subjects. When the 9 months data was released a following … Continue reading First Impressions From Simufilam Data on Open Label 12 Month Trial. $SAVA Simufilam Blarcamesine $AVXL
The Nature Of Balrcamesine Mechanism Of Action. The detractors of $AVXL always was list the closely unknown MOA. Most drugs are working in one point in some specific pathway. Their mechanism of action can be easly indentified by a single molecule they substitute for or interact with. The MOA for Blarcamesine is so vague and … Continue reading Is Authism To Be Affected by Blacamesine? It Seems Like It. $AVXL
Is Anavex Corroborating Efficacy of Balcamesine in Azheimer's Trials Or Is It Taking From The Big Pharma Playbook The "Biomarker Cure"? On the webpage of Alzheimer's Association International Conference held in San Diego, USA July 31-August 2 2022 folowing information about poster by Anavex can be found. The title of the poster is; Study of … Continue reading Blarcamesine: “Biomarker Cure” or Strong Efficacy AAIC San Diego 2022 $AVXL Anavex2-73
Source Article link: https://medicalxpress.com/news/2022-02-team-cells-tools-huntington-als.html So.... When neuron become strassed, like in inflammation or infection, they produce proteins in respnse. In order to produce protein they need to read the right part of their DNA, and then transcribe that into messengerRNA. Then mRNA is used to create chain of amino-acids (translation) which then is folded into … Continue reading The Mystery of Familial and Sporadic Neurodegenerative Diseases Expalined. Is A Cure Found, Soon? $AVXL Blarcamesine
More Research Papers Pointing to SIGMAR1 Agonists As Possible Drugs For Alzheimer's and Parkinson's Please, read this article on the cell stress and its effect of misfolded protein in cells. Link: https://medicalxpress.com/news/2022-05-stressed-cells-clues-build-up-toxic.html In some sense this article could not be possible without the imaging technology which allows to visualize the transition from misfolded proteins to … Continue reading That Little Cell Stress That Does It….Or Right Chaperone Protein For Right Misfolded Protein In Alzheimer’s and Parkinson’s. $AVXL Blarcamesine.
Disclaimers .. Disclaimers... But It Has Been Said by Chief Medical Officer That..... I place a standard disclaimer so that I won't be sued if somebody loses any money following this blog. Just read for entertainment (isn't it pretty funny? 😉 ) but don't invest. LOL. Nevertheless, the Chief Medical Officer on March 14, 2022 … Continue reading Institutional Investors Bet Equally on $AVXL and $SAVA Prospects. Will Results of $AVXL Alzheimer’s Phase 2b/3 Alter This? $SAVA $AVXL
Study Looks At Mitochondria In Genetic Model Of Parkinson's The fabled energy machines of the human cell, Mitochondria, have been for long regarded as ancient organisms which evolved from symbiotic organism into indispensable organels of human cells (animal and plant cells). The vestige of this process is the fact that Mitochondria posses their own DNA, … Continue reading Blarcamesine Has Been All About Mitochondrial Health For Years. Now, Parkinson’s Study Looks At Mitochondrial Health. $AVXL
One Picture Worth Few Drugs.... Section of AD/PD Conference 2022 Poster presented by Anavex Life Sciences. The full poster can be downloaded at https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_ff6b864593fb4418ab306474dd535d35.pdf Before I delve into the pretty picture here I shall reference the UPDRS content as it is undoubtfully of great value in understanding the implications of this section of the poster. … Continue reading Looking Under The Hood of PDD Phase 2 Blarcamsine Results. $AVXL $ANVS
Returning To My Old Friend... I have found outside of any paywall a very usefull paper as it looked at about six years of following probable Alzheimer's patients population of some 300 to 400 subjects. I derived many of my conclusions on Blarcamesine performance from this paper's content. The many assertion this paper was making … Continue reading Does 93% Of Patients Going Into Open Label Extension Bode Well For Blarcamesine Or Not?